Graphite Bio Secures $150 Million Series B Financing to Advance Pipeline of Next-Generation Gene Editing Therapies

March 15, 2021 Graphite Bio Secures $150 Million Series B Financing to Advance Pipeline of Next-Generation Gene Editing Therapies -  Total of $195 million raised to date to support expansion and clinical advancement of Graphite Bio pipeline of targeted gene integration therapies with curative potential -  The financing, led by RA Capital Management and Rock Springs Capital, included participation by other prominent...

Read more...

Graphite Bio Expands Leadership Team with Appointment of Jerry Cacia as Chief Technical Officer

February 24, 2021 Graphite Bio Expands Leadership Team with Appointment of Jerry Cacia as Chief Technical Officer -Distinguished biotech industry veteran brings depth of experience growing and scaling technical capabilities to deliver innovative medicines to patients -Appointment enables rapid progress toward establishment of manufacturing capabilities for next-generation gene editing therapies SOUTH SAN FRANCISCO, Calif., February 24, 2021 – Graphite Bio,...

Read more...

Jasper Therapeutics and Graphite Bio Announce Collaboration to Evaluate JSP191 as Conditioning Regimen for Novel Gene Replacement Therapy in Patients with XSCID

January 13, 2021 Jasper Therapeutics and Graphite Bio Announce Collaboration to Evaluate JSP191 as Conditioning Regimen for Novel Gene Replacement Therapy in Patients with XSCID REDWOOD CITY, Calif. January 13, 2021 -- Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, and Graphite Bio, Inc., a next-generation gene editing company focused on therapies that harness targeted gene integration...

Read more...

Graphite Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 8, 2021 Graphite Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., January 8, 2021 – Graphite Bio, a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced that Josh Lehrer, M.Phil, M.D., chief executive officer, will present an overview of Graphite...

Read more...

Graphite Bio Appoints Pharmaceutical Industry Veterans to Board of Directors

December 21, 2020 Graphite Bio Appoints Pharmaceutical Industry Veterans to Board of Directors - Joseph Jimenez, former CEO of Novartis, joins Board as an independent director - Perry Karsen, former Celgene executive, assumes Board Chair role SOUTH SAN FRANCISCO, Calif., December 21, 2020 – Graphite Bio, a next-generation gene editing company focused on therapies that harness targeted DNA integration to treat or cure...

Read more...

Graphite Bio Receives IND Clearance to Initiate Clinical Trial for Next-Generation Gene Editing Therapy GPH101 in Sickle Cell Disease

December 14, 2020 Graphite Bio Receives IND Clearance to Initiate Clinical Trial for Next-Generation Gene Editing Therapy GPH101 in Sickle Cell Disease - IND clearance for Phase 1/2 trial establishes Graphite Bio as the first company advancing potentially curative sickle cell gene editing therapy to restore normal hemoglobin expression - GPH101 harnesses the power of CRISPR and natural DNA repair mechanisms...

Read more...

Graphite Bio Expands Leadership Team with Accomplished Pharmaceutical Executives to Advance Programs to the Clinic and to Achieve Continued Business Growth

November 9, 2020 Graphite Bio Expands Leadership Team with Accomplished Pharmaceutical Executives to Advance Programs to the Clinic and to Achieve Continued Business Growth - Katherine Vega Stultz appointed as chief operating officer - Philip P. Gutry appointed as chief business officer and head of finance & investor relations - Executive hires follow appointment of Dr. Josh Lehrer as chief executive officer SOUTH...

Read more...

Graphite Bio Launches with $45 Million Series A Financing

Graphite Bio Launches with $45 Million Series A Financing -- Next-generation gene editing company launched by Versant Ventures with additional backing by Samsara BioCapital -- -- Core technology from Stanford founders Matt Porteus and Maria Grazia Roncarolo -- -- Josh Lehrer joins as CEO – SOUTH SAN FRANCISCO, Calif., September 16, 2020 -- Graphite Bio today announced a $45 million Series A financing...

Read more...